Background/Aim: Few clinical trials are available for advanced biliary tract carcinoma (BTC).
We conducted this randomized phase II clinical trial to explore efficacy and safety of 5 …

Objectives: We conducted a retrospective cohort study to compare 2 different chemotherapy
regimens for advanced biliary tract cancer (BTC). Methods: Records of patients …

Background: Although gemcitabine and platinum-based agents (GP) are currently regarded
as the standard chemotherapy for advanced biliary tract cancer (BTC), the prognosis …

Abstract Background Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a
clear survival advantage over gemcitabine alone and has become a new standard in …

Purpose Advanced biliary tract carcinoma (BTC) is a dismal disease with no standard
chemotherapy. We investigated efficacy and toxicity of biweekly oxaliplatin with 48-h …

Biliary tract carcinoma is a rare malignancy. We performed a comprehensive analysis of
published prospective clinical trials in advanced biliary tract carcinoma in an attempt to …

INTRODUCTION: First-line chemotherapy (CT1) is effective in advanced biliary tract cancer
(ABTC). The benefits of second-line chemotherapy (CT2) are unclear. METHODS: We …

Background Unresectable biliary tract carcinoma (BTC) is associated with a very poor
prognosis. To improve efficacy and tolerance of the 5-fluorouracil (5-FU)/cisplatin …

Objective: We aimed to evaluate the efficacy and safety of oxaliplatin, 5-fluorouracil (5-FU),
and leucovorin (LV)(FOLFOX-4) as second-line treatment in patients with advanced biliary …

Biliary tract carcinomas (BTC) present with minimal symptoms and thus they are often
diagnosed in advanced stages that require systemic therapy. Unfortunately, if not resected …